- Home
- GYRE vs HEPS Comparison
GYRE vs HEPS Comparison
Compare GYRE & HEPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- HEPS
- Stock Information
- Founded
- GYRE 2002
- HEPS 2000
- Country
- GYRE United States
- HEPS Turkey
- Employees
- GYRE N/A
- HEPS N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- HEPS Catalog/Specialty Distribution
- Sector
- GYRE Health Care
- HEPS Consumer Discretionary
- Exchange
- GYRE Nasdaq
- HEPS Nasdaq
- Market Cap
- GYRE 897.1M
- HEPS 909.5M
- IPO Year
- GYRE N/A
- HEPS 2021
- Fundamental
- Price
- GYRE $7.71
- HEPS $2.69
- Analyst Decision
- GYRE Strong Buy
- HEPS
- Analyst Count
- GYRE 1
- HEPS 0
- Target Price
- GYRE $18.00
- HEPS N/A
- AVG Volume (30 Days)
- GYRE 86.3K
- HEPS 251.9K
- Earning Date
- GYRE 08-11-2025
- HEPS 07-30-2025
- Dividend Yield
- GYRE N/A
- HEPS N/A
- EPS Growth
- GYRE N/A
- HEPS N/A
- EPS
- GYRE 0.02
- HEPS N/A
- Revenue
- GYRE $102,189,000.00
- HEPS $1,477,672,859.00
- Revenue This Year
- GYRE $21.04
- HEPS $37.44
- Revenue Next Year
- GYRE $89.64
- HEPS $28.46
- P/E Ratio
- GYRE $454.38
- HEPS N/A
- Revenue Growth
- GYRE N/A
- HEPS 49.45
- 52 Week Low
- GYRE $6.11
- HEPS $2.11
- 52 Week High
- GYRE $19.00
- HEPS $4.05
- Technical
- Relative Strength Index (RSI)
- GYRE 49.56
- HEPS 43.27
- Support Level
- GYRE $7.61
- HEPS $2.77
- Resistance Level
- GYRE $8.40
- HEPS $2.89
- Average True Range (ATR)
- GYRE 0.47
- HEPS 0.11
- MACD
- GYRE 0.01
- HEPS -0.02
- Stochastic Oscillator
- GYRE 34.29
- HEPS 4.76
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.